

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shiv Sagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018


Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2017

	Particulars	3 months ended	Corresponding 3 months
		30/06/2017	ended in the previous year
		Unaudited	Unaudited
I.	Revenue from operations (Gross of Excise)	5,483.40	5,172.74
II.	Other income	242.42	132.25
III.	Total Revenue (I + II)	5,725.82	5,304.99
IV.	Expenses:		
	Cost of materials consumed	3,872.19	3,604.65
	Purchases of Stock-in-Trade	-	-
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	10.38	116.48
	Employee benefits expense	187.29	178.09
	Finance costs	0.03	0.31
	Depreciation and amortization expense	41.50	51.35
	Excise duty paid	315.92	262.29
	Other expenses	596.32	561.68
	Total expenses (IV)	5,023.63	4,774.85
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	702.19	530.14
VI.	Exceptional items	-	-
VII.	Profit / (Loss) before tax (V - VI)	702.19	530.14
VIII.	Tax expense:		
	(1) Current tax	142.00	141.00
	(2) Deferred tax	-	-
	(3) Income tax of earlier Financial Years	-	-
		142.00	141.00
IX.	Profit/(Loss) for the period from continuing operations (VII-VIII)	560.19	389.14
X.	Profit/(loss) from discontinuing operations	-	-
XI.	Tax expense of discontinuing operations	-	-
XII.	Profit/(loss) from Discontinuing operations (after tax) [X - XI]	-	-
XIII.	Profit/(Loss) for the period (IX + XII)	560.19	389.14
XIV.	Other Comprehensive Income (net of Tax)	71.43	84.57
XV.	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	631.62	473.70
XVI.	Earnings per equity share (for continuing operations and discontinued operations) (Non annualised) (In Rs.)		
	(1) Basic	2.52	1.89
	(2) Diluted	2.52	1.89

NOTES:

- The above financial results for the quarter ended on June 30, 2017 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their Meeting held on September 08, 2017. The Statutory Auditors has carried out a limited review of the results for the quarter ended on June 30, 2017.



Pmsual

- 2) The Company has adopted Ind-AS from April 01, 2017 with a transition date of April 01, 2016 and accordingly this financial results have been prepared in accordance with the Ind-AS prescribed under section 133 of Companies Act, 2013. Consequently, the results for the quarter ended on June 30, 2016 have been restated to comply with Ind-AS. The reconciliation of Net Profit reported under previous IGAAP and restated Ind-AS is as under:

Particulars	Quarter Ended 30.06.2016 Unaudited (₹. In Lakhs)
Net profit as per previous IGAAP	389.14
Other Comprehensive Income (Net of tax)	
Add: Impact of measuring Investments at fair value	84.57
Total Comprehensive Income as per Ind-AS	473.70

- 3) The figures for the quarter ended on June 30, 2016 are Ind-AS compliant, but were not subject to limited review or audit. However, the management of the Company has exercised due diligence to ensure that the financial results provide a true and fair view of the Company's affairs.
- 4) Corresponding figures of the previous quarters have been regrouped, to make them comparable wherever necessary.
- 5) The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".

For Anuh Pharma Limited



Bipin N. Shah

Bipin N. Shah
Managing Director
(DIN: 00083244)

Place : Mumbai
Date : September 08, 2017

**LIMITED REVIEW REPORT ON QUARTERLY FINANCIAL RESULTS OF THE COMPANY
PURSUANT TO REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015**

TO THE BOARD OF DIRECTORS OF ANUH PHARMA LIMITED

We have reviewed the accompanying Statement of unaudited financial results of **Anuh Pharma Limited ("Company")** for the quarter ended on June 30, 2017 attached herewith, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016 and Circular no. CIR/CFD/CMD/15/2015 dated November 30, 2015. We draw attention to the fact that the figures for the corresponding quarter ended on June 30, 2016, including the reconciliation of profit/loss under Indian Accounting Standards ("**Ind AS**"), as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to our review.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("**SRE**") 2410, '*Review of Interim Financial Information performed by the Independent Auditor of the Entity*' issued by the Institute of Chartered Accountants of India ("**ICAI**"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Ind AS for '*Interim Financial Reporting*' (Ind AS 34), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 and Circular no. CIR/CFD/CMD/15/2015 dated November 30, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mumbai, India: September 8, 2017

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

S. I. Mogul

S.I. Mogul
Partner
Membership No. 5572